J Korean Ophthalmol Soc.
1992 May;33(5):501-506.
Ocular Hypotensive Effect of Levobunolol Hydrochloride
- Affiliations
-
- 1Glaucoma Service, Dr Hong's Eye Clinic, Seoul, Korea.
- 2Department of Ophthalmology, Yonsei University, College of Medicine, Seoul, Korea.
- 3Department of Ophthalmology, Medical College, Korea University, Seoul. Korea.
- 4Department of Ophthalmology, Kyung Hee University, College of Medicine, Seoul, Korea.
- 5Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea.
Abstract
- To estimate the clinical efficacy of a newly developed beta1 and beta2 - adrenoreceptor antagonist, levobunolol hydrochloride (Betagan), fifty six patients (96 eyes) with various types of glaucoma were enrolled in this study and were treated twice a day with 0.5% Betagan. Intraocular pressure (lOP), visual acuity, pupil size and cup/disc ratio were measured before and after Betagan treatment, at week 1, 2, 4, 8 and 12. The patients were also examined to check the subjective or objective local adverse reactions. All the patients showed significant reduction of lOP throughout the observation period without significant change of visual acuity, pupil size and cup/disc ratio. Additive hypotensive effect of Betagan was also noted when it was added to pilocarpine. In some patients, however, stinging sensation with tearing, photophobia, or foreign body sensation and punctate corneal erosion were noted after Betagan treatment; those were mild and transient.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Diurnal Variation and the Hypotensive Effect of Combined Therapy of Levobunolol and Dipivefrine in the Healthy Koreans and the Patients with Open Angle Glaucoma
- Effect of Ocular Hypotensives and Honan Intraocular Pressure Reducer on Ocular Tension after Retrobulbar Anesthesia
- The Short Time Antibacterial Effect of Tetracaine Hydrochloride(Pontocaine(R)): in vitro study
- Mydriatic Action of Phenylephrine Hydrochloride
- The Additive of Latanoprost 0.005% in Patients with Maximum Tolerated Medical Therapy Regimen
